Staar Surgical (STAA) Cash & Equivalents (2010 - 2026)

Staar Surgical has reported Cash & Equivalents for 17 years, with the latest figure at $131.9 million in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 23.83% year-over-year to $131.9 million; the trailing twelve-month figure through Apr 2026 stood at $131.9 million (down 23.83% YoY), and the FY2026 full-year result was $153.2 million, up 6.24% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $131.9 million, down from $153.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $224.0 million in Q1 2024, with the low at $86.5 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $154.9 million across 5 years, with a median of $164.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 56.7% — and 2024, when it soared 149.0%.
• Staar Surgical's Cash & Equivalents stood at $86.5 million in 2022, then surged by 111.65% to $183.0 million in 2023, then slipped by 21.24% to $144.2 million in 2024, then increased by 22.19% to $176.2 million in 2025, then fell by 25.14% to $131.9 million in 2026.
• The last three Cash & Equivalents figures came in at $131.9 million (Q2 2026), $153.2 million (Q1 2026), and $176.2 million (Q3 2025), per Business Quant data.